Journal
KIDNEY & BLOOD PRESSURE RESEARCH
Volume 30, Issue 4, Pages 248-252Publisher
KARGER
DOI: 10.1159/000104443
Keywords
chronic hemodialysis; chronic renal failure; erythropoietin; hypertension; nitric oxide; vascular access; hemodialysis
Ask authors/readers for more resources
Numerous uremic patients on hemodialysis have pulmonary hypertension attributable to the presence of arteriovenous fistulas, vascular calcification, and endothelial dysfunction due to alterations in the balance between vasoconstrictive and vasodilatory substances. For these reasons, the effects of recombinant human erythropoietin, a drug widely used in patients on dialysis, on the pulmonary circulation were studied. Some authors maintain that recombinant human erythropoietin has an antihypertensive effect, while others have observed that this hormone induces a reduction in pulmonary arterial pressure due to its vasoactive and stimulatory effects on endothelial and smooth muscle cell precursors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available